Compare · KDMN vs TLGT
KDMN vs TLGT
Side-by-side comparison of Kadmon Holdings, Inc. (KDMN) and Teligent, Inc. (TLGT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KDMN and TLGT operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- KDMN is the larger of the two at $1.67B, about 104.0x TLGT ($16.1M).
- KDMN has more recent analyst coverage (3 ratings vs 0 for TLGT).
- Company
- Kadmon Holdings, Inc.
- Teligent, Inc.
- Price
- $9.49+0.11%
- $0.17-13.18%
- Market cap
- $1.67B
- $16.1M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- n/a
- News (4w)
- 0
- 0
- Recent ratings
- 3
- 0
Kadmon Holdings, Inc.
Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (ROCK2), which is in Phase II clinical trial for the treatment of chronic graft-versus-host, as well as systemic sclerosis, an autoimmune disease characterized by chronic inflammation, fibrosis, and vascular damage; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. Kadmon Holdings, Inc., was incorporated in 2010 and is headquartered in New York, New York.
Teligent, Inc.
Teligent, Inc., a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company offers generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. It is also involved in contract manufacturing and development business, including the development, manufacturing, filling, and package of topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets. The company's topical semi-solid and liquid products are used in various applications that range from cosmetics and cosmeceuticals; and the prescription treatment of conditions, such as dermatitis, psoriasis, and eczema. It sells its products through national chain drug stores, drug wholesalers, distributors, and group purchasing organizations. The company was formerly known as IGI Laboratories, Inc. and changed its name to Teligent, Inc. in October 2015. Teligent, Inc. was incorporated in 1977 and is based in Buena, New Jersey.
Latest KDMN
- Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors
- Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
- SEC Form 15-12B filed by Kadmon Holdings, Inc.
- SEC Form EFFECT filed by Kadmon Holdings, Inc.
- SEC Form EFFECT filed by Kadmon Holdings, Inc.
- SEC Form 4: Flowers Cynthia Louise gifted 20,150 shares and returned $103,075 worth of shares to the company (10,850 units at $9.50), closing all direct ownership in the company
- SEC Form 4 filed by Cohen David E
- SEC Form 4 filed by Ryan John L
- SEC Form 4: Waksal Harlan returned $1,690,478 worth of shares to the company (177,945 units at $9.50), closing all direct ownership in the company
- SEC Form 4: Moss Gregory S. returned $167,874 worth of shares to the company (17,671 units at $9.50), closing all direct ownership in the company
Latest TLGT
- SEC Form 25-NSE filed by Teligent, Inc.
- Teligent, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Events That Accelerate or Increase a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Teligent to Pursue Asset Sale through Voluntary Chapter 11 Process
- SEC Form 3 filed by new insider Benesch Joseph
- SEC Form 3 filed by new insider Lozynski Alyssa
- Teligent, Inc. filed SEC Form 8-K: Leadership Update
- Teligent, Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SEC Form 10-Q filed by Teligent, Inc.
- Teligent, Inc. Announces Second Quarter 2021 Earnings Report and Provides Business Update
- Teligent, Inc. to Hold Conference Call for Second Quarter 2021 Financial Results on Monday, August 16, 2021